---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-014972"
form_type: "8-K"
ticker: "ZBH"
cik: "0001136869"
company_name: "ZIMMER BIOMET HOLDINGS, INC."
filed_at: "2025-02-06T23:59:59+00:00"
generated_at: "2026-05-27T01:25:36.997180+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Zimmer Biomet Q4 sales $2.02B (+4.9% CC), adj. EPS $2.31; guides FY2025 adj. EPS $8.15-$8.35

## Summary
- Q4 net sales $2.023B (+4.9% constant currency); Q4 adjusted diluted EPS $2.31.
- Full-year net sales $7.679B (+4.8% CC); full-year adjusted diluted EPS $8.00.
- FY2025 guidance: constant currency revenue growth 3%-5%; adjusted diluted EPS $8.15-$8.35.
- Announced definitive agreement to acquire Paragon 28 (FNA) for foot & ankle segment; terms not disclosed.
- Received FDA PMA for Oxford Cementless Partial Knee and FDA 510(k) for OsseoFit Stemless Shoulder.

## SEC filing metadata
- accession: 0000950170-25-014972
- form_type: 8-K
- ticker: ZBH
- cik: 0001136869
- company_name: ZIMMER BIOMET HOLDINGS, INC.
- filed_at: 2025-02-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1136869/000095017025014972/0000950170-25-014972-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1136869/000095017025014972/zbh-20250206.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-014972
- JSON: https://secwatch.observer/filing/0000950170-25-014972.json
- Plain text: https://secwatch.observer/filing/0000950170-25-014972.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.